대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	The effect of febuxostat on the preservation of glomerular filtration rate In nondiabetic patients with CKD
저자	Inseong PARK1, *Sangheon SONG1, Harin RHEE1, Jongman PARK1, Ilyoung KIM2, Eunyoung SEONG1, Dongwon LEE2, Soobong LEE2, Ihmsoo KWAK1
출판정보	2017; 2017(1):
키워드	febuxostat, CKD
초록	Objectives : Since allopurinol was limited in patients with CKD because of severe adverse effects, recently febuxostat has been used in CKD patients with or without gout. To date, several reports have suggested that febuxostat could be helpful to preserve the renal function in patients with CKD. In this study, we evaluated the effect of febuxostat in lowering serum UA and protection of renal function in non-diabetic patients with CKD. Methods : In retrospective observational study, thirty seven non-dialytic & nondiabetic CKD patients who had treatment with allopurinol for 1 year or longer before switching to febuxostat. Those patients’ uric acid level didn’t effectively decreased irrespective of allopurinol treatment and thus we changed medication into febuxostat. After that, all enrolled patients have been treated with febuxostat for at least 1 year. Serum UA concentration and estimated glomerular filtration rate (eGFR) were compared between allopurinol era and febuxostat era during 1 year before and after switching from allopurinol to febuxostat. Results : The mean serum UA concentration was 7.86 ± 1.64 mg/dL before switching to febuxostat for 12 months. After switching to febuxostat, the mean serum UA concentration was significantly reduced at first 3 months (4.67 ± 1.93mg/dL) and those level was maintained at 6 month, and 12 month (5.07 ± 2.24 and 4.90 ± 2.07mg/dL). There was a significant difference in the slope of eGFR change between allopurinol era and febuxostat era (-3.84 ± 5.77 vs. 3.16 ± 8.18mL/min/1.73m2/year, p=0.001). Twenty three patients (23/37, 62.1%) showed the improvement of eGFR during febuxostat treatment compared with allopurinol treatment era. Conclusions : Febuxostat has superior potency for urate lowering and may have the renal protective effect in non-diabetic CKD patients.
원문(PDF)	PDF 원문보기

목록

위로가기